Clinical trials are essential for evaluating potential new treatments, advancing the standard of care, and improving patient outcomes, yet only about five percent of Americans participate in them. As it stands, patients from lower-income and rural communities often face substantial economic barriers to participation, including lost wages, time, and out-of-pocket costs for transportation and lodging.

What can Congress do to make clinical trials more accessible to patients? What are the biggest barriers to participation? And what does this all mean for the future of drug development?

Join us for The Hill Talks: Breaking Down Financial Barriers to Clinical Trial Participation, a bipartisan program examining this issue with lawmakers and patient advocates with a critical focus on health equity.